Granulocyte colony-stimulating factor

ApprovedSmall molecule

Granulocyte colony-stimulating factor is one of 774 small molecule programs targeting Acute Liver Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

773

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

Hepatic FailureActive, not recruiting

Muscular DystrophyActive, not recruiting

Aplastic AnemiaActive, not recruiting

Lung CancerActive, not recruiting

LymphomaActive, not recruiting

Bone PainActive, not recruiting

NeuroblastomaActive, not recruiting

Coronary AtherosclerosisActive, not recruiting

Dystrophic Epidermolysis BullosaActive, not recruiting

Acute Liver FailurePreclinical

Active, not recruiting

Hepatic FailureApproved

Active, not recruiting

Muscular DystrophyPhase 1

Active, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Bone PainPreclinical

Active, not recruiting

NeuroblastomaPreclinical

Active, not recruiting

Coronary AtherosclerosisPhase 1

Active, not recruiting

Dystrophic Epidermolysis BullosaPhase 2

Active, not recruiting

Showing 10 of 36 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Granulocyte colony-stimulating factor

Sanofi

Approved

1 2

Avastin

Megace

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

Merck & Co.

Preclinical

2 6

Voltaren

Novartis

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Multiple Myeloma

NCT03909412

Q4 2026

ApprovedRecruiting

Early-Stage Breast Cancer

NCT05753618

N/ARecruiting

Biliary Atresia

NCT06708572

Phase 3Not yet recruiting

Poor Graft Function

NCT05669079

Phase 3Not yet recruiting

Poor Graft Function

NCT05907499

Phase 2Recruiting

Neuroblastoma

NCT02605421

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia8 trials

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

Completed·—·Phase 1/2·NCT01690507·29 enrolled

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting·KKura Oncology, Inc.·Phase 1·NCT06001788·171 enrolled

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT06034470·30 enrolled

Show 5 more trials

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·SShanxi Bethune Hospital·Phase 3·NCT05726110·50 enrolled

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT06007911

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Completed·UUniversity of Washington·Phase 2·NCT03012672·50 enrolled

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated· Astellas logo

Astellas·Phase 1/2·NCT04240002·9 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05449899·232 enrolled

Multiple Myeloma6 trials

Autologous Transplant for Multiple Myeloma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00177047·363 enrolled

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02851056·14 enrolled

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Completed· Sanofi logo

Sanofi··NCT00741780·164 enrolled

Show 3 more trials

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Completed·SSiddhartha Ganguly·Phase 2·NCT02703779·101 enrolled

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

Completed· Sanofi logo

Sanofi·Phase 2·NCT01753453·23 enrolled

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Recruiting·HHackensack Meridian Health·Phase 1·NCT03909412·18 enrolled

Lymphoma4 trials

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Completed·PPolish Lymphoma Research Group·Phase 2·NCT01481272·77 enrolled

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

Completed· Sanofi logo

Sanofi··NCT00741325·178 enrolled

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Completed· Sanofi logo

Sanofi·Phase 3·NCT01767714·100 enrolled

Show 1 more trial

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Completed· Sanofi logo

Sanofi·Phase 4·NCT01164475·61 enrolled

Granulocyte Colony Stimulating Factor3 trials

Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)

Completed·EEmory University·N/A·NCT00231309·10 enrolled

Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF

Unknown status·GGovind Ballabh Pant Hospital·N/A·NCT01036932·50 enrolled

The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes

Recruiting·NNewlife Fertility Centre·Phase 4·NCT06174298·300 enrolled

Conditioning3 trials

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02744742·202 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05453552·242 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04713956·242 enrolled

54 more indications

Stem Cells2 trials

Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00005782·12 enrolled

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00082329·9 enrolled

Neuroblastoma2 trials

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01526603·13 enrolled

Biliary Atresia2 trials

GCSF Adjunct Therapy for Biliary Atresia

Completed·—·Phase 1·NCT03395028·6 enrolled

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

Recruiting·NNational Liver Institute, Egypt·N/A·NCT06708572·40 enrolled

Stem Cell Transplant2 trials

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT04002115·2 enrolled

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

G-CSF2 trials

G-CSF for Granulocyte Donation

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001842·16 enrolled

Influence of G-CSF and EPO on Associative Learning and Motor Skills

Completed·UUniversity Hospital Muenster·Phase 2·NCT00298597·180 enrolled

Poor Graft Function2 trials

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05669079·100 enrolled

Decitabine for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled

Acute Leukemia2 trials

Total Marrow Irradiation for Refractory Acute Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00686556·12 enrolled

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05805072·20 enrolled

Acute Lymphoblastic Leukemia1 trial

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

Aplastic Anemia1 trial

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06752694·20 enrolled

Pediatric Cancer1 trial

Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients

Unknown status·UUniversity of Mississippi Medical Center·Phase 4·NCT03823950·150 enrolled

Treatment1 trial

The Effect of GCSF in the Treatment of ALS Patients

Completed·TTehran University of Medical Sciences·Phase 2/3·NCT01825551·40 enrolled

Breast Cancer1 trial

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Completed·MMedSIR·Phase 2·NCT05520723·50 enrolled

Relapsed or Refractory1 trial

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting·—·Phase 2·NCT06316960·50 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00556127·94 enrolled

Non-Small Cell Lung Cancer1 trial

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Terminated·PProacta, Incorporated·Phase 2·NCT00862134·42 enrolled

Memory1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06158828·68 enrolled

Hematopoietic Stem Cell Transplant1 trial

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Recruiting·—·Phase 2·NCT06059391·216 enrolled

Amyotrophic Lateral Sclerosis1 trial

G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response

Completed·PPeking University·Phase 2·NCT00397423·40 enrolled

Cirrhosis1 trial

To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis

Completed·SSir Ganga Ram Hospital·Phase 3·NCT02642003·259 enrolled

Endometriosis1 trial

Effect of Granulocyte Colony-stimulating Factor on Clinical Pregnancy Rate in Patients With Endometriosis

Unknown status·AAmira Magdi Guergues Selim·Phase 2·NCT03549728·88 enrolled

Hematopoietic Cell Transplantation1 trial

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 1·NCT02750254·5 enrolled

Stem Cell1 trial

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00651937·80 enrolled

Dystrophic epidermolysis bullosa1 trial

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Completed·VVanderbilt University Medical Center·Phase 2·NCT01538862·7 enrolled

Dilated Cardiomyopathy1 trial

Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy

Completed·BBarts & The London NHS Trust·Phase 2·NCT01302171·60 enrolled

Frozen Embryo Transfer1 trial

Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer

Completed·WWael Elbanna Clinic·Phase 4·NCT03945812·665 enrolled

Infusion1 trial

Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF

Completed·—··NCT04998279·100 enrolled

Acute Liver Failure1 trial

Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT01341951·60 enrolled

Bone Marrow Failure Syndrome1 trial

G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Terminated·EEmory University·N/A·NCT00228813·8 enrolled

Glioblastoma1 trial

G-CSF After Chemo-radiation in Patients With Glioblastoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06649851·60 enrolled

Type 1 Diabetes1 trial

ATG-GCSF in New Onset Type 1 Diabetes

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02215200·89 enrolled

Bone pain1 trial

G-CSF-Induced Bone Pain and Supportive Care Approaches

Completed·—··NCT07192770·225 enrolled

Metastatic1 trial

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

Completed·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT02268695·541 enrolled

Neuroendocrine Carcinoma1 trial

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03042780·2 enrolled

Lung Cancer1 trial

A Study for Participants With Small-Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01025284·64 enrolled

Elderly1 trial

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 3·NCT02961257·196 enrolled

Coronary Atherosclerosis1 trial

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Completed·MMayo Clinic·Phase 1·NCT03471611·21 enrolled

Chemotherapy1 trial

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02611492·265 enrolled

TIA1 trial

An Evaluation of the Spectra Optia CMNC Collection Procedure

Completed·TTerumo BCT·N/A·NCT02253160·23 enrolled

Triple-Negative Breast Cancer1 trial

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT04584112·83 enrolled

Relapsed/Refractory AML1 trial

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed·WWashington University School of Medicine·Phase 1·NCT01161550·11 enrolled

Prevention1 trial

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03018223·32 enrolled

Prostate Cancer1 trial

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Withdrawn·—·Phase 2·NCT01750866

Colorectal Cancer1 trial

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT06509906·3 enrolled

Malignancy1 trial

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Unknown status·—·Phase 4·NCT02784561·80 enrolled

Muscular Dystrophy1 trial

Efficacy Safety of Granulocyte Colony-stimulating Factor Treatment Children and Adolescents With Muscular Dystrophy

Unknown status·MMedical University of Bialystok·Phase 1·NCT02814110·27 enrolled

Hepatic failure1 trial

RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure

Unknown status·—·Phase 4·NCT02331745·140 enrolled

Myelodysplastic Syndrome1 trial

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Active, not recruiting·—·Phase 2·NCT04262843·33 enrolled

Heart Failure1 trial

Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure

Completed·BBarts & The London NHS Trust·Phase 2/3·NCT00747708·148 enrolled

Myocardial Infarction1 trial

Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair

Unknown status·UUniversity of Ottawa·Phase 2/3·NCT00394498·86 enrolled

Thin Endometrium1 trial

A Single-Center Randomized Controlled Trial of Intrauterine G-CSF Infusion for Improving Pregnancy Outcomes in Patients With Thin Endometrium

Not yet recruiting·NNanjing University·Phase 3·NCT07692672·620 enrolled

Early-stage Breast Cancer1 trial

A Randomized Pragmatic Trial Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (REaCT-OGF)

Recruiting·OOttawa Hospital Research Institute·Approved·NCT05753618·242 enrolled

DLBCL1 trial

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05139017·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 85 trial records for Granulocyte colony-stimulating factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Granulocyte colony-stimulating factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Granulocyte colony-stimulating factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Granulocyte colony-stimulating factor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Acute Myeloid Leukemia8 trials

Multiple Myeloma6 trials

Lymphoma4 trials

Granulocyte Colony Stimulating Factor3 trials

Conditioning3 trials

Stem Cells2 trials

Neuroblastoma2 trials

Biliary Atresia2 trials

Stem Cell Transplant2 trials

G-CSF2 trials

Poor Graft Function2 trials

Acute Leukemia2 trials

Acute Lymphoblastic Leukemia1 trial

Aplastic Anemia1 trial

Pediatric Cancer1 trial

Treatment1 trial

Breast Cancer1 trial

Relapsed or Refractory1 trial

Diffuse Large B-Cell Lymphoma1 trial

Non-Small Cell Lung Cancer1 trial

Memory1 trial

Hematopoietic Stem Cell Transplant1 trial

Amyotrophic Lateral Sclerosis1 trial

Cirrhosis1 trial

Endometriosis1 trial

Hematopoietic Cell Transplantation1 trial

Stem Cell1 trial

Dystrophic epidermolysis bullosa1 trial

Dilated Cardiomyopathy1 trial

Frozen Embryo Transfer1 trial

Infusion1 trial

Acute Liver Failure1 trial

Bone Marrow Failure Syndrome1 trial

Glioblastoma1 trial

Type 1 Diabetes1 trial

Bone pain1 trial

Metastatic1 trial

Neuroendocrine Carcinoma1 trial

Lung Cancer1 trial

Elderly1 trial

Coronary Atherosclerosis1 trial

Chemotherapy1 trial

TIA1 trial

Triple-Negative Breast Cancer1 trial

Relapsed/Refractory AML1 trial

Prevention1 trial

Prostate Cancer1 trial

Colorectal Cancer1 trial

Malignancy1 trial

Induction Therapy1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Muscular Dystrophy1 trial

Hepatic failure1 trial

Myelodysplastic Syndrome1 trial

Heart Failure1 trial

Myocardial Infarction1 trial

Thin Endometrium1 trial

Early-stage Breast Cancer1 trial

DLBCL1 trial

References

Drug Info

Quick Facts

Related News